In patients with cancer, SARS-CoV-2 (COVID-19) can contribute to increasing morbidity and mortality and decreased survival was found in patients with hematological and intrathoracic malignancies, poor performance status, comorbidities, and increased age. Patients with hematological malignancies who were treated with stem cell transplantation and anti-CD-20 antibody demonstrated lower rates of seroconversion, compared to COVID-19-infected-cancer patients. Patients with hematological malignancies might have substantially compromised B-cell and T-cell responses.

Full Text

Published Version
Open DOI Link

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call